{"id":322608,"date":"2025-05-11T14:13:23","date_gmt":"2025-05-11T18:13:23","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=322608"},"modified":"2025-05-11T14:13:23","modified_gmt":"2025-05-11T18:13:23","slug":"non-alpha-il-2-mutein-a-cuban-hope-for-cancer","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/","title":{"rendered":"Non-alpha IL-2 Mutein: a Cuban hope for cancer"},"content":{"rendered":"

On April 18, <\/span>Granma<\/span><\/i> newspaper published <\/span>an article<\/span><\/a> about a clinical trial in patients with solid tumors involving a new drug: non-alpha IL-2 Mutein. The study is being conducted at the Hermanos Ameijeiras Clinical and Surgical Hospital in Havana. According to Dr. Vilma Fleites Calvo, an oncology specialist at the aforementioned institution, positive results have been obtained so far.<\/span><\/p>\n

The <\/span>Granma<\/span><\/i> article clarifies that the ongoing research aims to \u201cverify the safety and efficacy of an escalating dose\u201d of the drug, obtained at the Center for Molecular Immunology (CIM). The patients participating in this study are in an advanced stage of their disease and have already undergone other treatments.<\/span><\/p>\n

What is non-alpha IL-2 Mutein? How does this drug work? What impact might it have on cancer patients? How long is the road ahead? We will discuss these topics in this article.<\/span><\/p>\n

History of a drug<\/b><\/h4>\n

Whenever we talk about a new drug, I like to highlight the decades of research required to achieve a scientific breakthrough, the fruit of the work of a team of extremely talented and dedicated people. This case is no exception.<\/span><\/p>\n

The first reference to the product currently being studied at the Hermanos Ameijeiras Hospital is <\/span>the patent application<\/span><\/a> filed in June 2011 with the World Intellectual Property Organization. It was conducted by the CIM and a group of researchers led by <\/span>Dr. Kalet Le\u00f3n Monz\u00f3n<\/b><\/a>.\u00a0<\/span><\/p>\n

Of course, the patent did not refer to the finished product, but to a group of polypeptides with immunomodulatory properties derived from interleukin 2 (IL-2), developed for use in the treatment of cancer and chronic infections. Polypeptides are molecules composed of amino acids, which are the substances that make up proteins. On the other hand, the fact that they have \u201cimmunomodulatory properties\u201d means that they are capable of acting on the immune system, modifying its activity for the benefit of patients.<\/span><\/p>\n

To fully understand what we are talking about, we must refer to IL-2. It is a protein produced by T lymphocytes, which are the body\u2019s defensive cells and whose function is to increase the production and activity of this same cell group.<\/span><\/p>\n

According to <\/span>a specialized article<\/span><\/a>, IL-2 was discovered in 1976 and named \u201cT cell growth factor.\u201d This molecule is composed of three chains, named alpha, beta, and gamma. These chains function as arms that connect with receptors on the membrane of immune cells, initiating a set of cellular response mechanisms on which their function depends.<\/span><\/p>\n

IL-2 was approved in 1992 for the treatment of metastatic renal cell carcinoma, an aggressive type of cancer that affects the kidneys, and then, in 1998, for metastatic melanoma, a skin cancer. However, its effects, although positive in some cases, did not meet the expectations of the scientific community.<\/span><\/p>\n

According to <\/span>an article<\/span><\/a> published in the journal <\/span>Anales de la Academia de Ciencias de Cuba<\/span><\/i>, patients with renal and epithelial carcinomas only benefit in 15 to 30% of cases. This is because IL-2, in addition to enhancing the action of effector lymphocytes \u2014 which have strictly defensive functions \u2014 also activates regulatory lymphocytes, whose main function is to limit the activity of the former. In other words, it would be like simultaneously turning the immune system on and off in a cancer patient.<\/span><\/p>\n

Additionally, the drug\u2019s safety profile is poor, as the adverse effects are intense and, in many cases, require discontinuation of treatment. This was the motivation of the Cuban research team when developing this group of candidate substances: to achieve a drug that combines safety and effectiveness for the treatment of various oncological pathologies.<\/span><\/p>\n

Non-alpha IL-2 mutein<\/b><\/h4>\n

A key element in the functioning of this molecule is the different degree of affinity of the alpha, beta and gamma chains with the different types of T lymphocytes. It is known that the alpha chains induce the activation and proliferation of regulatory lymphocytes, while the beta and gamma chains act preferentially on effector lymphocytes, that is, those that act directly against cancer cells and infectious agents.<\/span><\/p>\n

What did the Cuban researchers do? Using bioinformatics techniques, they developed a series of candidates and then determined which one was best suited to becoming a drug.<\/span><\/p>\n

Why is it called a \u201cmutein\u201d? Because during the production process, a mutation was induced in the DNA chain of the genes that encode the \u201cwild protein,\u201d that is, the IL-2 that we all have in our bodies. In this case, the DNA sequence was modified in four locations, resulting in a molecule that retained most of its structure but was sufficiently distinct from the original to acquire new properties. This was explained in an article published in June 2013 in <\/span>The Journal of Immunology<\/span><\/i>.<\/span><\/p>\n

The mutations were concentrated in the alpha chain, resulting in a lower affinity of regulatory T cell (Treg) receptors for the mutein, compared to wild-type IL-2 (IL-2S), hence its name \u201cnon-alpha.\u201d In contrast, in another experiment, the non-alpha IL-2 mutein showed similar behavior to IL-2S in activating effector T cells.<\/span><\/p>\n

Later, the antimetastatic effect of the mutein was evaluated in experimental mice, and its effect was found to be superior to that of IL-2S. This result was repeated in other experimental models, reinforcing the conviction of the usefulness of this drug. Finally, the safety of the mutein was compared with IL-2S, and it was observed that it induced far fewer adverse effects in treated mice.<\/span><\/p>\n

The hypothesis that this effect was due to the non-alpha mutein\u2019s ability to alter the ratio of effector and regulatory lymphocytes was confirmed in <\/span>a new study\u00a0<\/span><\/a>published in 2022 in the journal <\/span>Frontiers in Immunology<\/span><\/i>. In this case, equal doses of mutein and IL-2S were used, and it was found that mice treated with mutein had 23% more effector T cells than those treated with IL-2S. In contrast, Treg levels increased in mice that received IL-2S.<\/span><\/p>\n

Other encouraging results of this study were the demonstration that the mutein is capable of reducing tumor growth, decreasing metastatic activity, and improving survival in mice with cancer.<\/span><\/p>\n

A long road ahead<\/b><\/h4>\n

With all of the above, the doors were open for the next phase of research: testing the mutein in humans. And that\u2019s where it is currently at.<\/span><\/p>\n

From a rational standpoint, it seems logical to assume that this drug will offer good results in terms of its ability to reduce tumor and metastatic activity. Furthermore, it is expected to have a favorable safety profile, with few adverse reactions, which would allow its use in a large number of patients.<\/span><\/p>\n

However, all of this remains to be proven. The non-alpha mutein still has a long way to go, during which it will have to confirm whether the expectations placed on it are met. We will have to wait for new results to be published. Although work on this product has been going on for more than fifteen years, it would not be unreasonable to assume that in no less than five years it could be submitted for approval by the Cuban regulatory agency and the other 16 countries where CIM holds its patent. That\u2019s how science works.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Currently in clinical trials with advanced cancer patients in Havana, this new drug could mark a turning point in immunotherapy for solid tumors.<\/p>\n","protected":false},"author":12345834,"featured_media":322610,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[13902,13918],"tags":[34782,19256,34658],"ppma_author":[34560],"class_list":["post-322608","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cuba","category-health-in-cuba","tag-cancer","tag-featured","tag-health-in-cuba"],"acf":[],"yoast_head":"\nNon-alpha IL-2 Mutein: a Cuban hope for cancer | OnCubaNews English<\/title>\n<meta name=\"description\" content=\"Currently in clinical trials with advanced cancer patients in Havana, this new drug could mark a turning point in immunotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Non-alpha IL-2 Mutein: a Cuban hope for cancer | OnCubaNews English\" \/>\n<meta property=\"og:description\" content=\"Currently in clinical trials with advanced cancer patients in Havana, this new drug could mark a turning point in immunotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"OnCubaNews English\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-11T18:13:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1800\" \/>\n\t<meta property=\"og:image:height\" content=\"1350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Carlos Alberto Gonz\u00e1lez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Carlos Alberto Gonz\u00e1lez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/\"},\"author\":{\"name\":\"carlosalbertogonzalez\",\"@id\":\"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439\"},\"headline\":\"Non-alpha IL-2 Mutein: a Cuban hope for cancer\",\"datePublished\":\"2025-05-11T18:13:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/\"},\"wordCount\":1184,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg\",\"keywords\":[\"cancer\",\"featured\",\"Health in Cuba\"],\"articleSection\":[\"Cuba\",\"Health in Cuba\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\/\/oncubanews.com\/en\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/\",\"url\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/\",\"name\":\"Non-alpha IL-2 Mutein: a Cuban hope for cancer | OnCubaNews English\",\"isPartOf\":{\"@id\":\"https:\/\/oncubanews.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg\",\"datePublished\":\"2025-05-11T18:13:23+00:00\",\"author\":{\"@id\":\"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439\"},\"description\":\"Currently in clinical trials with advanced cancer patients in Havana, this new drug could mark a turning point in immunotherapy.\",\"breadcrumb\":{\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#primaryimage\",\"url\":\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg\",\"contentUrl\":\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg\",\"width\":1800,\"height\":1350,\"caption\":\"Photo: Kaloian.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/oncubanews.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Non-alpha IL-2 Mutein: a Cuban hope for cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/oncubanews.com\/en\/#website\",\"url\":\"https:\/\/oncubanews.com\/en\/\",\"name\":\"OnCubaNews English\",\"description\":\"Revista sobre Cuba\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/oncubanews.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439\",\"name\":\"carlosalbertogonzalez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/oncubanews.com\/en\/#\/schema\/person\/image\/96692c05f4b2ce956c2e5f967d928992\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g\",\"caption\":\"carlosalbertogonzalez\"},\"url\":\"https:\/\/oncubanews.com\/en\/author\/carlosalbertogonzalez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Non-alpha IL-2 Mutein: a Cuban hope for cancer | OnCubaNews English","description":"Currently in clinical trials with advanced cancer patients in Havana, this new drug could mark a turning point in immunotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Non-alpha IL-2 Mutein: a Cuban hope for cancer | OnCubaNews English","og_description":"Currently in clinical trials with advanced cancer patients in Havana, this new drug could mark a turning point in immunotherapy.","og_url":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/","og_site_name":"OnCubaNews English","article_published_time":"2025-05-11T18:13:23+00:00","og_image":[{"width":1800,"height":1350,"url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg","type":"image\/jpeg"}],"author":"Carlos Alberto Gonz\u00e1lez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Carlos Alberto Gonz\u00e1lez","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#article","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/"},"author":{"name":"carlosalbertogonzalez","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439"},"headline":"Non-alpha IL-2 Mutein: a Cuban hope for cancer","datePublished":"2025-05-11T18:13:23+00:00","mainEntityOfPage":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/"},"wordCount":1184,"commentCount":0,"image":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg","keywords":["cancer","featured","Health in Cuba"],"articleSection":["Cuba","Health in Cuba"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/oncubanews.com\/en\/#organization"}},{"@type":"WebPage","@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/","url":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/","name":"Non-alpha IL-2 Mutein: a Cuban hope for cancer | OnCubaNews English","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#primaryimage"},"image":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg","datePublished":"2025-05-11T18:13:23+00:00","author":{"@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439"},"description":"Currently in clinical trials with advanced cancer patients in Havana, this new drug could mark a turning point in immunotherapy.","breadcrumb":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#primaryimage","url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg","contentUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2025\/05\/Cuba-2022-fotos-Kaloian28-de-enero-de-2022-3-1.jpg","width":1800,"height":1350,"caption":"Photo: Kaloian."},{"@type":"BreadcrumbList","@id":"https:\/\/oncubanews.com\/en\/cuba\/non-alpha-il-2-mutein-a-cuban-hope-for-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/oncubanews.com\/en\/"},{"@type":"ListItem","position":2,"name":"Non-alpha IL-2 Mutein: a Cuban hope for cancer"}]},{"@type":"WebSite","@id":"https:\/\/oncubanews.com\/en\/#website","url":"https:\/\/oncubanews.com\/en\/","name":"OnCubaNews English","description":"Revista sobre Cuba","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oncubanews.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/2c76245ec7769cd9f458b8f35d9c6439","name":"carlosalbertogonzalez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/image\/96692c05f4b2ce956c2e5f967d928992","url":"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g","caption":"carlosalbertogonzalez"},"url":"https:\/\/oncubanews.com\/en\/author\/carlosalbertogonzalez\/"}]}},"authors":[{"term_id":34560,"user_id":12345834,"is_guest":0,"slug":"carlosalbertogonzalez","display_name":"Carlos Alberto Gonz\u00e1lez","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/c968a39df93ed0958f5b64a69d66bd00852902a862efe1ca443ee5c6cca4cbca?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/322608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/users\/12345834"}],"replies":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/comments?post=322608"}],"version-history":[{"count":3,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/322608\/revisions"}],"predecessor-version":[{"id":322609,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/322608\/revisions\/322609"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media\/322610"}],"wp:attachment":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media?parent=322608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/categories?post=322608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/tags?post=322608"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/ppma_author?post=322608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}